Pharsight

Drugs that contain Tavaborole

1. Kerydin patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566290 ANACOR PHARMS INC Boron-containing small molecules
Feb, 2026

(1 year, 9 months from now)

US9566289 ANACOR PHARMS INC Boron-containing small molecules
Feb, 2026

(1 year, 9 months from now)

US9549938 ANACOR PHARMS INC Boron-containing small molecules
Feb, 2026

(1 year, 9 months from now)

US9572823 ANACOR PHARMS INC Boron-containing small molecules
Feb, 2026

(1 year, 9 months from now)

US9549938

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Aug, 2026

(2 years from now)

US9566290

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Aug, 2026

(2 years from now)

US9572823

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Aug, 2026

(2 years from now)

US9566289

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Aug, 2026

(2 years from now)

US7767657 ANACOR PHARMS INC Boron-containing small molecules
May, 2027

(3 years from now)

US7582621 ANACOR PHARMS INC Boron-containing small molecules
May, 2027

(3 years from now)

US7582621

(Pediatric)

ANACOR PHARMS INC Boron-containing small molecules
Nov, 2027

(3 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 07, 2019
Pediatric Exclusivity(PED) Jan 07, 2020

NCE-1 date: 07 January, 2019

Market Authorisation Date: 07 July, 2014

Treatment: Treatment of onychomychosis of a toenail caused by trichophyton rubrum or trichophyton mentagrophytes; Treatment of onychomycosis of a toenail; Treatment for onychomycosis that is tinea unguium

Dosage: SOLUTION;TOPICAL

How can I launch a generic of KERYDIN before it's drug patent expiration?
More Information on Dosage

KERYDIN family patents

Family Patents